Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib

Ann Hematol. 2016 Jan;95(2):349-50. doi: 10.1007/s00277-015-2518-5. Epub 2015 Oct 13.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Female
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Janus Kinase 2 / antagonists & inhibitors*
  • Janus Kinase 2 / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Middle Aged
  • Myeloproliferative Disorders / diagnosis
  • Myeloproliferative Disorders / drug therapy
  • Myeloproliferative Disorders / genetics
  • Nitriles
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use*
  • Pyrimidines
  • Treatment Outcome

Substances

  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib
  • Fusion Proteins, bcr-abl
  • JAK2 protein, human
  • Janus Kinase 2